Phase 2 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old (or the minimum age required by local regulations) with a body mass index (BMI) between 18.0 and 35.0 — a standard measure of body weight relative to height.
- People who have a specific type of hepatitis B virus (HBV) marker in their blood called HBeAg-positive (for Part 1 of the trial), or HBeAg-negative (for Part 2).
- People whose blood tests show a certain level of hepatitis B surface antigen (HBsAg) above the laboratory's minimum detectable level.
- People whose blood tests show a hepatitis B virus level (HBV DNA) of at least 20,000 IU/mL.
- People with a confirmed diagnosis of chronic (long-term) hepatitis B infection and liver enzyme levels (ALT) that are not more than 8 times the upper limit of the normal range during screening.
- People who have never been treated with hepatitis B antiviral medicines or experimental HBV treatments, OR people who have not used any such treatments within the past 6 months (or longer, depending on the specific medicine).
Who may not be able to join:
- People who also have hepatitis A, C, D, or E, or HIV, or any other significant liver disease not caused by hepatitis B.
- People whose blood tests show antibodies against hepatitis B surface antigen (anti-HBs), which can indicate past infection or immunity.
- People who have a current or past diagnosis of cirrhosis (severe scarring of the liver).
- People with liver scarring (fibrosis) classified as Metavir Score F3 or higher — a medical grading scale for liver damage (confirm with trial site).
- People who have had, or currently show signs of, the liver losing its ability to function properly (hepatic decompensation).
- People whose liver ultrasound shows signs of liver cancer (hepatocellular carcinoma).
- People who have taken part in another clinical trial or used an experimental medicine or device within the past 4 weeks (or longer, depending on the specific medicine).
- People whose blood screening tests show certain abnormal results, including: liver enzyme AST levels more than 8 times the upper limit of normal; bilirubin levels more than 1.2 times the upper limit of normal (unless a condition called Gilbert's syndrome is suspected); or blood clotting ratio (INR) more than 1.2 times the upper limit of normal.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (800) 466-6059
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
HBeAg positive: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target detected or target not detected); HBeAg negative: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target not detected)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.